Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BCellMax Life 〉NGS-SMSEQ®

NGS-SMSEQ®

NGS-SMSEQ®

CellMax Life's SMSEQ® platform has an analytical specificity of ≥99.999%. This patented technology, combined with years of research and development advancements enables CellMax to offer comprehensive genetic tests.

Request for Collaboration
Overview
CellMax SMSEQ® Platform

Analytical specificity of ≥99.999%

CellMax Life's liquid biopsy blood test uses next generation sequencing technology to detect gene alterations.

The patented technology, combined with years of research and development advancements enables CellMax to offer an extremely cost effective and liquid biopsy, profiling 73 genes from circulating tumor DNA (ctDNA), to identify and assess actionable genomic alterations using CellMax Life's proprietary single-molecule-sequencing SMSEQ® platform.

The SMSEQ® platform has a greater than 99.999% specificity and an analytical detection limit of 0.1%.


Application

Personalized Precision Medicine. Detect Early. Treat Early.

1. DNA Genetic Cancer Risk Test :



utilizing an expanded 98 gene panel across 25 cancers using personal DNA from a saliva or blood sample. Cancers include: Breast、Ovarian、Endometrium (Uterine)、Myometrium (Uterine)、Prostate Gland、Stomach、Large Bowel & Rectal、Lung and Pleura、Small Intestines、Esophagus、Urinary Tract & Bladder、Exocrine Pancreas、Kidneys、Cervix、Skin、Bone、Thyroid、Gland、Liver、Soft Tissue、Misc. Endocrine Glands、Blood、Head & Neck、Central Nervous System、Peripheral Nervous System.



2. LBx :




    

3. NCCN Lung Cancer Panel


 
Collaboration Options
Licensing
Co-development
Marketing & Distribution
Investment
More Information
People who like this also like
  • Platform_BioSeizer™Platform_BioSeizer™
  • SNP-630SNP-630
  • low-alcohol formulation (iLEF) platformlow-alcohol formulation (iLEF) platform
  • Patented CMx® PlatformPatented CMx® Platform
  • Carrier screening for fragile X syndromeCarrier screening for fragile X syndrome
  • NGS-SMSEQ®NGS-SMSEQ®
  • Pilot scale up development and manufacturingPilot scale up development and manufacturing
  • Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)
  • RD statusRD status
  • Medical Image Playing System and MethodMedical Image Playing System and Method